Manganese-based immunotherapy synergized with novel supramolecular hydrogel: Advancing localized immune activation strategies in squamous cell carcinoma

Head and neck squamous cell carcinoma (HNSCC) presents significant challenges for its treatment, especially for the treatment aimed at preserving maxillofacial function due to its complex anatomical structure, resistance to radiotherapy and chemotherapy, and low intertumoral immunogenicity. In this...

Full description

Saved in:
Bibliographic Details
Main Authors: Tianqing Wang, Xiaopei Hu, Xin Tian, Ying Wang, Shiyu Zhang, Silu Sun, Ning Ji, Xiaobo Luo, Qianming Chen, Xin Zeng, Hang Zhao, Jing Li
Format: Article
Language:English
Published: Elsevier 2025-02-01
Series:Materials & Design
Subjects:
Online Access:http://www.sciencedirect.com/science/article/pii/S0264127525000528
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1832590001009852416
author Tianqing Wang
Xiaopei Hu
Xin Tian
Ying Wang
Shiyu Zhang
Silu Sun
Ning Ji
Xiaobo Luo
Qianming Chen
Xin Zeng
Hang Zhao
Jing Li
author_facet Tianqing Wang
Xiaopei Hu
Xin Tian
Ying Wang
Shiyu Zhang
Silu Sun
Ning Ji
Xiaobo Luo
Qianming Chen
Xin Zeng
Hang Zhao
Jing Li
author_sort Tianqing Wang
collection DOAJ
description Head and neck squamous cell carcinoma (HNSCC) presents significant challenges for its treatment, especially for the treatment aimed at preserving maxillofacial function due to its complex anatomical structure, resistance to radiotherapy and chemotherapy, and low intertumoral immunogenicity. In this study, we introduce a novel approach employing manganese-based immunotherapy (Mn-IT) for the effective treatment of HNSCC. Firstly, we used a tumor-immune cell co-culture system to demonstrate that Mn2+ enhances immune cytotoxicity in HNSCC via cGAS-STING activation. Subsequently, we used an orthotopic transplant tumor model to validate that Mn-IT exerts antitumor effects and immune activation in HNSCC. Subsequently, to enhance efficacy and reduce the immune-related side effects of Mn-IT, we utilized the biocompatibility and immunomodulatory potential of inosine to develop a supramolecular hydrogel, guanosine-phenylboronic-tannic acid-phenylboronic-inosine (G-TA-I), through a green and straightforward method. The G-TA-I hydrogel is characterized by its dynamic borate ester-based structure, facilitating localized, sustained release of therapeutics. This hydrogel not only exhibited acceptable biocompatibility and biodegradability but also was able to load and sustain the release of Mn2+ and PD-1 antibody in situ. Finally, we adopted a range of mouse tumor models to reveal that G-TA-I supramolecular hydrogel drug delivery system loaded with Mn2+ and PD-1 antibody could efficiently activate local immunity, effectively combating the occurrence and progression of HNSCC. These findings indicate that the Mn-αPD-1-loaded in situ sustained-release G-TA-I hydrogel represents a novel, safe, and effective cancer therapeutic drug delivery system that can maximize the efficacy of immunotherapy and reduce the side effects of immunotherapy. This supramolecular hydrogel drug delivery system provides a basis for new therapeutic strategies for tumor types such as head and neck tumors that require maximal preservation of the structure and function of the diseased site.
format Article
id doaj-art-b379794442534d95a9efa137bd72a970
institution Kabale University
issn 0264-1275
language English
publishDate 2025-02-01
publisher Elsevier
record_format Article
series Materials & Design
spelling doaj-art-b379794442534d95a9efa137bd72a9702025-01-24T04:44:31ZengElsevierMaterials & Design0264-12752025-02-01250113632Manganese-based immunotherapy synergized with novel supramolecular hydrogel: Advancing localized immune activation strategies in squamous cell carcinomaTianqing Wang0Xiaopei Hu1Xin Tian2Ying Wang3Shiyu Zhang4Silu Sun5Ning Ji6Xiaobo Luo7Qianming Chen8Xin Zeng9Hang Zhao10Jing Li11State Key Laboratory of Oral Diseases & National Center for Stomatology, National Clinical Research Center for Oral Diseases, Research Unit of Oral Carcinogenesis and Management, Chinese Academy of Medical Sciences, West China Hospital of Stomatology, Sichuan University, Chengdu 610041, Sichuan, ChinaState Key Laboratory of Oral Diseases & National Center for Stomatology, National Clinical Research Center for Oral Diseases, Research Unit of Oral Carcinogenesis and Management, Chinese Academy of Medical Sciences, West China Hospital of Stomatology, Sichuan University, Chengdu 610041, Sichuan, ChinaState Key Laboratory of Oral Diseases & National Center for Stomatology, National Clinical Research Center for Oral Diseases, Research Unit of Oral Carcinogenesis and Management, Chinese Academy of Medical Sciences, West China Hospital of Stomatology, Sichuan University, Chengdu 610041, Sichuan, ChinaState Key Laboratory of Oral Diseases & National Center for Stomatology, National Clinical Research Center for Oral Diseases, Research Unit of Oral Carcinogenesis and Management, Chinese Academy of Medical Sciences, West China Hospital of Stomatology, Sichuan University, Chengdu 610041, Sichuan, ChinaState Key Laboratory of Oral Diseases & National Center for Stomatology, National Clinical Research Center for Oral Diseases, Research Unit of Oral Carcinogenesis and Management, Chinese Academy of Medical Sciences, West China Hospital of Stomatology, Sichuan University, Chengdu 610041, Sichuan, ChinaState Key Laboratory of Oral Diseases & National Center for Stomatology, National Clinical Research Center for Oral Diseases, Research Unit of Oral Carcinogenesis and Management, Chinese Academy of Medical Sciences, West China Hospital of Stomatology, Sichuan University, Chengdu 610041, Sichuan, ChinaState Key Laboratory of Oral Diseases & National Center for Stomatology, National Clinical Research Center for Oral Diseases, Research Unit of Oral Carcinogenesis and Management, Chinese Academy of Medical Sciences, West China Hospital of Stomatology, Sichuan University, Chengdu 610041, Sichuan, ChinaState Key Laboratory of Oral Diseases & National Center for Stomatology, National Clinical Research Center for Oral Diseases, Research Unit of Oral Carcinogenesis and Management, Chinese Academy of Medical Sciences, West China Hospital of Stomatology, Sichuan University, Chengdu 610041, Sichuan, ChinaState Key Laboratory of Oral Diseases & National Center for Stomatology, National Clinical Research Center for Oral Diseases, Research Unit of Oral Carcinogenesis and Management, Chinese Academy of Medical Sciences, West China Hospital of Stomatology, Sichuan University, Chengdu 610041, Sichuan, ChinaCorresponding authors.; State Key Laboratory of Oral Diseases & National Center for Stomatology, National Clinical Research Center for Oral Diseases, Research Unit of Oral Carcinogenesis and Management, Chinese Academy of Medical Sciences, West China Hospital of Stomatology, Sichuan University, Chengdu 610041, Sichuan, ChinaCorresponding authors.; State Key Laboratory of Oral Diseases & National Center for Stomatology, National Clinical Research Center for Oral Diseases, Research Unit of Oral Carcinogenesis and Management, Chinese Academy of Medical Sciences, West China Hospital of Stomatology, Sichuan University, Chengdu 610041, Sichuan, ChinaCorresponding authors.; State Key Laboratory of Oral Diseases & National Center for Stomatology, National Clinical Research Center for Oral Diseases, Research Unit of Oral Carcinogenesis and Management, Chinese Academy of Medical Sciences, West China Hospital of Stomatology, Sichuan University, Chengdu 610041, Sichuan, ChinaHead and neck squamous cell carcinoma (HNSCC) presents significant challenges for its treatment, especially for the treatment aimed at preserving maxillofacial function due to its complex anatomical structure, resistance to radiotherapy and chemotherapy, and low intertumoral immunogenicity. In this study, we introduce a novel approach employing manganese-based immunotherapy (Mn-IT) for the effective treatment of HNSCC. Firstly, we used a tumor-immune cell co-culture system to demonstrate that Mn2+ enhances immune cytotoxicity in HNSCC via cGAS-STING activation. Subsequently, we used an orthotopic transplant tumor model to validate that Mn-IT exerts antitumor effects and immune activation in HNSCC. Subsequently, to enhance efficacy and reduce the immune-related side effects of Mn-IT, we utilized the biocompatibility and immunomodulatory potential of inosine to develop a supramolecular hydrogel, guanosine-phenylboronic-tannic acid-phenylboronic-inosine (G-TA-I), through a green and straightforward method. The G-TA-I hydrogel is characterized by its dynamic borate ester-based structure, facilitating localized, sustained release of therapeutics. This hydrogel not only exhibited acceptable biocompatibility and biodegradability but also was able to load and sustain the release of Mn2+ and PD-1 antibody in situ. Finally, we adopted a range of mouse tumor models to reveal that G-TA-I supramolecular hydrogel drug delivery system loaded with Mn2+ and PD-1 antibody could efficiently activate local immunity, effectively combating the occurrence and progression of HNSCC. These findings indicate that the Mn-αPD-1-loaded in situ sustained-release G-TA-I hydrogel represents a novel, safe, and effective cancer therapeutic drug delivery system that can maximize the efficacy of immunotherapy and reduce the side effects of immunotherapy. This supramolecular hydrogel drug delivery system provides a basis for new therapeutic strategies for tumor types such as head and neck tumors that require maximal preservation of the structure and function of the diseased site.http://www.sciencedirect.com/science/article/pii/S0264127525000528HNSCCPD-1 blockadeManganese-based immunotherapyDrug delivery systemSupramolecular Hydrogel
spellingShingle Tianqing Wang
Xiaopei Hu
Xin Tian
Ying Wang
Shiyu Zhang
Silu Sun
Ning Ji
Xiaobo Luo
Qianming Chen
Xin Zeng
Hang Zhao
Jing Li
Manganese-based immunotherapy synergized with novel supramolecular hydrogel: Advancing localized immune activation strategies in squamous cell carcinoma
Materials & Design
HNSCC
PD-1 blockade
Manganese-based immunotherapy
Drug delivery system
Supramolecular Hydrogel
title Manganese-based immunotherapy synergized with novel supramolecular hydrogel: Advancing localized immune activation strategies in squamous cell carcinoma
title_full Manganese-based immunotherapy synergized with novel supramolecular hydrogel: Advancing localized immune activation strategies in squamous cell carcinoma
title_fullStr Manganese-based immunotherapy synergized with novel supramolecular hydrogel: Advancing localized immune activation strategies in squamous cell carcinoma
title_full_unstemmed Manganese-based immunotherapy synergized with novel supramolecular hydrogel: Advancing localized immune activation strategies in squamous cell carcinoma
title_short Manganese-based immunotherapy synergized with novel supramolecular hydrogel: Advancing localized immune activation strategies in squamous cell carcinoma
title_sort manganese based immunotherapy synergized with novel supramolecular hydrogel advancing localized immune activation strategies in squamous cell carcinoma
topic HNSCC
PD-1 blockade
Manganese-based immunotherapy
Drug delivery system
Supramolecular Hydrogel
url http://www.sciencedirect.com/science/article/pii/S0264127525000528
work_keys_str_mv AT tianqingwang manganesebasedimmunotherapysynergizedwithnovelsupramolecularhydrogeladvancinglocalizedimmuneactivationstrategiesinsquamouscellcarcinoma
AT xiaopeihu manganesebasedimmunotherapysynergizedwithnovelsupramolecularhydrogeladvancinglocalizedimmuneactivationstrategiesinsquamouscellcarcinoma
AT xintian manganesebasedimmunotherapysynergizedwithnovelsupramolecularhydrogeladvancinglocalizedimmuneactivationstrategiesinsquamouscellcarcinoma
AT yingwang manganesebasedimmunotherapysynergizedwithnovelsupramolecularhydrogeladvancinglocalizedimmuneactivationstrategiesinsquamouscellcarcinoma
AT shiyuzhang manganesebasedimmunotherapysynergizedwithnovelsupramolecularhydrogeladvancinglocalizedimmuneactivationstrategiesinsquamouscellcarcinoma
AT silusun manganesebasedimmunotherapysynergizedwithnovelsupramolecularhydrogeladvancinglocalizedimmuneactivationstrategiesinsquamouscellcarcinoma
AT ningji manganesebasedimmunotherapysynergizedwithnovelsupramolecularhydrogeladvancinglocalizedimmuneactivationstrategiesinsquamouscellcarcinoma
AT xiaoboluo manganesebasedimmunotherapysynergizedwithnovelsupramolecularhydrogeladvancinglocalizedimmuneactivationstrategiesinsquamouscellcarcinoma
AT qianmingchen manganesebasedimmunotherapysynergizedwithnovelsupramolecularhydrogeladvancinglocalizedimmuneactivationstrategiesinsquamouscellcarcinoma
AT xinzeng manganesebasedimmunotherapysynergizedwithnovelsupramolecularhydrogeladvancinglocalizedimmuneactivationstrategiesinsquamouscellcarcinoma
AT hangzhao manganesebasedimmunotherapysynergizedwithnovelsupramolecularhydrogeladvancinglocalizedimmuneactivationstrategiesinsquamouscellcarcinoma
AT jingli manganesebasedimmunotherapysynergizedwithnovelsupramolecularhydrogeladvancinglocalizedimmuneactivationstrategiesinsquamouscellcarcinoma